Urinary Excretion and Renal Clearance of Allopurinol in Male Gout Patients

Bilal Ahmed

Authors

Bilal Ahmed

Keywords:

Abstract

Drugs removed from the body either without changing from its original form or in the form of its metabolite. Allopurinol drug decreases uric acid level in blood and it is used for the treatment of gout and tumor lysis syndrome. Allopurinol and its active metabolite oxipurinol stop the function of xanthine oxidase which forms uric acid from xanthine and hypoxanthine. In this study a quantitative assay using high-performance liquid chromatography (HPLC) with UVdetection was used as a method for quantification of allopurinol and oxipurinol in human serum and urine samples of gout patients after allopurinol administration. The urinary excretion and renal clearance was determined in male gout patients. Blood and urine samples of the human male patients of gout (n=10) after the oral administration of 300mg drug were taken at different time intervals. Results of this study show that there is slow metabolism of allopurinol inside body due to its extensive bonding with blood proteins. Statistical analysis was performed by expressing all the data as mean and ± standard error of mean. The effect of pH and diuresis on renal clearance of allopurinol was studied by regression analysis.

Downloads

How to Cite

Urinary Excretion and Renal Clearance of Allopurinol in Male Gout Patients. (2014). Global Journal of Medical Research, 13(F6), 5-13. https://medicalresearchjournal.org/index.php/GJMR/article/view/467

Download Citation

References

Avram, Z, E Krishnan (2008) where nephrology meets rheumatology. 47, 960-964.

Ki Choi, Jong Lee, Su Kim, Nam Kim, Kyoung Moon, Kwang Park, Hee Bom, Young Kang (1993) Cimetidine Improves the Accuracy of Creatinine Clearance as an Indicator for Glomerular Filtration Rate. 8(1), 28-34.

N David (2004) High performance liquid chromatography in pharmaceutical bioanalysis. A handbook of bioanalysis and drug metabolism. 8, 213-214.

E Dowling, F Prasna, D Tongella (2001) Inhibitory action of allopurinol. 7, 713-719.

W Ganong (2005) Allopurinol excretory mechanism. 22, 697-699.

A Guyton, J Hall (2000) Drug metabolism. Text book of medical physiology. 301, 306-307.

K Hande, R Noone, W Stone (1984) Severe Allopurinol Toxicity. Description and Guidelines for Prevention in Patients With Renal Insufficiency. 131(6), 1258-1259.

L Domenico, S Gioia, G Ciofani, F Cuccurullo (1998) Antioxidant activity of allopurinol on copper-catalysed human lipoprotein oxidation. 409, 265-268.

J Lin, S Auricle, M Pasanen, R Juvonen (1988) D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. 25, 411-425.

K Mattheus, L Reinders, N Nijdam (2007) A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection. 45, 312-317.

M Namazi (2004) Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. 4, 349-353.

I Perez, I Hernando, Villar (2005) Basic clinical importance of drugs. 17, 129-133.

A Rodolfo, R Juvencio (2003) Density functional theory study of the free and cobalt-coordinated allopurinol ligand. 664, 91-109.

D Seldin (2004) The development of the clearance concept. Biomedical importance of allopurinol. 1, 166-171.

A Shoji, H Yamanaka, N Kamatani (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis. 51, 321-325.

L Stamp, P Gow, K Sharples, B Raill (2000) The optimal use of allopurinol: an audit of allopurinol use in South Auckland. 30(5), 567-572.

R Steel, J Torrie, D Dickey (2001) Principles and procedures of statistics: A biochemical approach. 3, 877-879.

M Takada, H Okada, T Kotake, N Kawato, M Saito, M Nakai, T Gunji, M Shibakawa (2005) Appropriate dosing regimen of allopurinol in Japanese patients1. 30(4), 407-412.

Y Tetsuya, Y Moriwaki, S Takahashi, Z Tsutsumi, J Yamakita, K Higashino (1997) Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. 46, 1473-1476.

Martin Veller, J Botha, Russel Britz, Gary Gecelter, Peter Beale, Larry Margolius, Kevin Meyers, Peter Thompson, Anthony Meyers, J Myburgh (1994) Renal allograft preservation: A comparison of University of Wisconsin solution and of hypothermic continuous pulsatile perfusion. 8(2pt1), 97-100.

O Konrad, L Bonafe, B Steinmann (2002) Remark on utility and error rates of the allopurinol test in detecting mild ornithine transcarbamylase deficiency. 48, 180-183.

Takashi Iwanaga, Daisuke Kobayashi, Masamichi Hirayama, Tomoji Maeda, Ikumi Tamai (2005) INVOLVEMENT OF URIC ACID TRANSPORTER IN INCREASED RENAL CLEARANCE OF THE XANTHINE OXIDASE INHIBITOR OXYPURINOL INDUCED BY A URICOSURIC AGENT, BENZBROMARONE. 33(12), 1791-1795.

M Jeffrey, J Brian, B Shillingstad, D Youngelman, M Schweitzer, R Lash ; Hande, K, E Reed, B Chabner (1998) Pretreatment with allopurinol diminishes 9. 23, 598-605.